IGHE and allergic disease: Ligelizumab also binds the Fc portion of IgE but shares significantly more overlap with the binding epitope of FcɛR1 on IgE than omalizumab, suggestive of a potential therapeutic advantage in FcɛRI-driven allergic disease.